Ignite Creation Date:
2024-05-06 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05335473
Status:
RECRUITING
Last Update Posted:
2023-04-06
First Post:
2022-04-13
Brief Title:
Iribrine Plus Tucidinostat in the Treatment of HRHER2 Advanced Breast Cancer After CDK46 Inhibitor Failure
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Study Overview
Official Title:
Phase I b II Clinical Study of Iribrine Mesylate Plus Tucidinostat in the Treatment of HRHER2- Locally Relapsed or Metastatic Breast Cancer After Previous CDK46 Inhibitor Failure
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the safety and efficacy of Eribulin plus Tucidinostat amine in patients with HR HER2-advanced metastatic breast cancer
Detailed Description:
To explore the dose-limiting toxicity DLT maximum tolerated dose MTD and Phase II recommended dose RP2D of the regimen of Eribulin plus Tucidinostat and to initially explore the safety and efficacy of Eribulin plus Tucidinostat amine in patients with HR HER2-advanced metastatic breast cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CSIIT-C28 | OTHER | CS | None |